TrialAmerican journal of hematology2021

Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.

Jonathan L Kaufman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.